Placeholder Banner

BIO Comments on FDA Draft Guidance on Rare Diseases: Natural History Studies for Drug Development

May 24, 2019

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Rare Diseases: Natural History Studies for Drug Development.

BIO says the guidance is as an important communication tool for the FDA and Sponsors. It ensures Sponsors have the appropriate information for developing new therapies for patients with rare diseases ­– especially since many rare diseases do not have FDA-approved treatment.

BIO provides recommendations on how to improve natural history studies so the FDA can have robust data for making regulatory decisions, as well as how to improve the guidance. BIO recommends the draft guidance align with other draft guidance covering natural history studies, like Rare Diseases: Common Issues in Drug Development

 

Download Full Comments Below
BIO Comment Letter Natural History Studies Rare Disease Drug Development FDA–2017-D-0481
Read the full comment letter below
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…